Skip to content
Back to Parent Page

VASCADE MVP®

Early Ambulation. Simple. Proven.
VASCADE MVP® vascular closure system provides rapid hemostasis for electrophysiology (EP) procedures, eliminating the need for manual compression and enabling patients to get up and moving earlier. In the AMBULATE Trial,1 the VASCADE MVP system has been proven to reduce time to ambulation by 64%, improve patient satisfaction by 63% and reduce opioid use post procedure by 58%. The VASCADE MVP system is the first and only FDA-approved closure device for same day discharge as well as for use in multi-stick, multi-limb cardiac ablation procedures.2 Watch the video

Haemonetics Vascular Closure

VASCADE MVP® System

Make a selection to learn more

VASCADE MVP® System

Select an icon to learn more
Haemonetics Vascular Closure Vascade MVP

The first and only FDA-approved closure device for same day discharge

and multi-stick, multi-limb access following cardiac ablations2,3

• Dedicated to mid-bore 6-12F ID (Max 15F OD) multiaccess venous closure
• Simple and easy to use
• Single operator
• No sutures or material left in the vessel
• Extravascular design
• No permanent or intraluminal implants
• Bioabsorbable and thrombogenic collagen plug
• Expands to fill tissue tract

Ordering Information

To place an order please contact Customer Service.
Model NumberDescriptionOrder Quantity
700-500DX-05U 5 French (Inner Diameter)1 Box (5 devices per box)
Model NumberDescriptionOrder Quantity
700-580I-05U 6/7 French (Inner Diameter)1 Box (5 devices per box)
Model NumberDescriptionOrder Quantity
800-612C-10U  6-12 French (Inner Diameter)1 Box (10 devices per box)
Product NameModel NumberDescriptionOrder Quantity
CATALYST II
500-580C-10U 5-7 French
1 Box (10 devices per box)
CATALYST III
600-580CP-10U
5-7 French
1 Box (10 devices per box) 
1. Natale A, et al. Venous vascular closure system versus manual compression following multiple access electrophysiology procedures: The AMBULATE Trial. JACC Clin Electrophysiol October 2019. DOI: 10.1016/j.jacep.2019.08.013.
2.  IFUs of commercially available venous vascular closure devices: VASCADE MVP®, MYNXGRIP®, Perclose ProGlide™ and Perclose ProStyle™. As of 1 Oct 2022.
3. Catheter-based cardiac ablations requiring two or more venous access sites within the same limb. See VASCADE MVP IFU 3972 Indications for Use.
4. AMBULATE IMPACT Study, April 2018. EX 4372, data on file at Haemonetics.
5. AMBULATE Same Day Discharge Registry Retrospective Study: NCT04538781.
6. AMBULATE Same Day Discharge Registry Prospective Studies (Paroxysmal AF): NCT04203329.
7. For venous access site closure-related complications through 15-day follow up or standard of care follow up, and for procedure- related complications the next day.
8. Major venous access site closure-related complications through the follow-up period.
LIT 5832 REV AA

Connect with Vascular Closure


Haemonetics Vascular Closure LinkedIn    Haemonetics Vascular Closure Twitter